The one-two punch: TIM-3 blockade targets immune and tumor cells to knock out pediatric brain tumors
- PMID: 37863067
- DOI: 10.1016/j.ccell.2023.09.016
The one-two punch: TIM-3 blockade targets immune and tumor cells to knock out pediatric brain tumors
Abstract
Diffuse midline gliomas (DMGs) pose treatment challenges due to their location within the brainstem and invasive nature. Although classical immune checkpoint inhibitors have demonstrated limited success in clinical trials, Ausejo-Mauleon et al. demonstrate TIM-3 is an effective DMG strategy, targeting both immune and tumor cells for dual therapeutic benefit.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
Comment on
-
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory.Cancer Cell. 2023 Nov 13;41(11):1911-1926.e8. doi: 10.1016/j.ccell.2023.09.001. Epub 2023 Oct 5. Cancer Cell. 2023. PMID: 37802053 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
